BCM
GSK icon

Brookstone Capital Management’s GSK GSK Stock Holding History

Brookstone Capital Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.99M Sell
37,960
-399
-1% -$21.1K 0.02% 496
2026
Q1 		$2.12M Buy
38,359
+3,427
+10% +$186K 0.02% 455
2025
Q4 		$1.71M Buy
34,932
+464
+1% +$21.6K 0.02% 485
2025
Q3 		$1.49M Buy
34,468
+1,251
+4% +$48.9K 0.02% 510
2025
Q2 		$1.28M Sell
33,217
-373
-1% -$14.3K 0.02% 509
2025
Q1 		$1.3M Buy
33,590
+1,889
+6% +$69.2K 0.02% 493
2024
Q4 		$1.07M Buy
31,701
+5,244
+20% +$189K 0.02% 512
2024
Q3 		$1.08M Buy
26,457
+718
+3% +$29.4K 0.02% 505
2024
Q2 		$1.03M Sell
25,739
-911
-3% -$38.3K 0.02% 496
2024
Q1 		$1.14M Sell
26,650
-1,027
-4% -$42.4K 0.02% 459
2023
Q4 		$1.03M Sell
27,677
-566
-2% -$20.3K 0.02% 451
2023
Q3 		$1,000K Buy
28,243
+2,570
+10% +$91.2K 0.02% 423
2023
Q2 		$868K Sell
25,673
-220
-0.8% -$7.89K 0.02% 462
2023
Q1 		$968K Buy
25,893
+5,373
+26% +$188K 0.02% 462
2022
Q4 		$717K Buy
20,520
+1,624
+9% +$54.1K 0.01% 503
2022
Q3 		$574K Sell
18,896
-20,866
-52% -$791K 0.01% 539
2022
Q2 		$2.1M Buy
39,762
+23,697
+148% +$1.31M 0.05% 283
2022
Q1 		$933K Sell
16,065
-20,039
-56% -$1.09M 0.02% 433
2021
Q4 		$1.98M Buy
36,104
+291
+0.8% +$15.1K 0.03% 270
2021
Q3 		$1.74M Buy
35,813
+415
+1% +$20.8K 0.03% 284
2021
Q2 		$1.79M Buy
35,398
+21,724
+159% +$1.04M 0.03% 276
2021
Q1 		$610K Buy
13,674
+6,224
+84% +$283K 0.02% 327
2020
Q4 		$343K Buy
7,450
+1,011
+16% +$46.4K 0.01% 364
2020
Q3 		$303K Buy
+6,439
New +$323K 0.01% 334
2015
Q4 		– Sell
-124
Closed -$6K – 449
2015
Q3 		$6K Sell
124
-1,345
-92% -$70K ﹤0.01% 1338
2015
Q2 		$76K Buy
+1,469
New +$82.7K 0.01% 385

Other funds holding GSK

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
KFP
Keystone Financial Planning Cleveland, Ohio $388M AUM 16.66% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return
BB
Bell Bank Fargo, North Dakota $2.62B AUM 23.93% 1-Year Est. Return
KIC
Keating Investment Counselors Delray Beach, Florida $364M AUM 22.11% 1-Year Est. Return
GHAM
Gilman Hill Asset Management New Canaan, Connecticut $731M AUM 19.41% 1-Year Est. Return
AWAG
ARS Wealth Advisors Group St. Petersburg, Florida $1.28B AUM 24.51% 1-Year Est. Return
HAI
Hennessy Advisors Inc Novato, California $3.13B AUM 77.26% 1-Year Est. Return

Brookstone Capital Management's GSK Position: Q2 2026 in Review

Brookstone Capital Management reduced its GSK (GSK) stake by 1% in Q2 2026, selling an estimated $21.1K and leaving 37,960 shares worth $1.99M. The position accounts for 0.02% of the portfolio, ranked #496.

Brookstone Capital Management first reported a position in GSK in Q2 2015 and has held it in 26 quarters since. The position peaked at $2.12M in Q1 2026. 161 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Brookstone Capital Management held 37,960 shares of GSK worth $1.99M as of Q2 2026.
  • Brookstone Capital Management sold 399 GSK shares in Q2 2026, an estimated $21.1K.
  • GSK made up 0.02% of Brookstone Capital Management's portfolio in Q2 2026, its #496 holding.
  • Brookstone Capital Management first reported a position in GSK in Q2 2015 and has held it in 26 quarters since.
  • Brookstone Capital Management's GSK position peaked at $2.12M in Q1 2026.
  • 161 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Brookstone Capital Management's 13F filing for Q2 2026, filed 15 Jul 2026.